Amgen

NEULASTA

Manufacturer:

Amgen

Neulasta HCPCS:

J2506

HCPCS Code Descriptor:

Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

Category:

J Code

Neulasta NDCs:

55513-0190-01, 55513-0192-01

Primary Type:

Oncology Colony Stimulating Factor

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Neulasta:

NEULASTA is an Oncology Colony Stimulating Factor drug manufactured by Amgen and administered via the Subcutaneous route of administration. The J Code: J2506 is aligned to the drug NEULASTA.

ACCESS PRICING AND MORE BY REGISTERING

J2506 Added Date:

January 1, 2022

J2506 Effective Date:

April 1, 2023

J2506 Termination Date:

HCPCS Active

Neulasta billing and coding information can be found through Amgen at the link below:
Neulasta patient assistance information can be found through Amgen Assist at the URL: https://www.amgenassist.com/copay
NEULASTA prescribing information can be found at the link below:
Information regarding NEULASTA’s side effects can be found at MedlinePlus